Relievant Medsystems, Inc., a privately held medical device company pioneering the therapeutic use of nerve ablation within vertebral bodies for the treatment of chronic low back pain (CLBP), announced that it has secured $36 million in equity financing. New Enterprise Associates (NEA) led the financing with participation from Canaan Partners, Emergent Medical Partners and Morgenthaler Ventures. INTRACEPT® Intraosseous Nerve Ablation System recently received FDA clearance to treat chronic low back pain (CLBP) based on results of landmark SMART clinical trial.
